0
Everything we know about the UK’s novel, emergent strain of COVID-19
As a new COVID-19 strain emerges in the southeast of England that appears to be more infectious than previous strains, what do…
Browsing: Disease Area
0
How has COVID-19 impacted research?
Discover the vast impacts of the COVID-19 pandemic on the lab research community: from funding cuts, to PhD students changing…
0
Pfizer/BioNTech COVID-19 vaccine approved for use by UK regulator
Pfizer and BioNTech’s COVID-19 vaccine has been approved for use by the UK’s regulator, MHRA, making it the first COVID-19…
0
What are the advantages of the Oxford—AstraZeneca COVID-19 vaccine?
While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly…
0
Antimicrobials: handle with care
World Antimicrobial Awareness Week 2020 (WAAW; 18–24 November) is upon us. Infectious Diseases Hub takes a look at the past,…
0
Moderna’s COVID-19 vaccine demonstrates 94.5% efficacy
Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s…
0
Pfizer and BioNTech’s COVID-19 vaccine 90% effective in Phase III trial
The first set of data from Pfizer (NY, USA) and BioNTech’s (Mainz, Germany) Phase III clinical trial for their COVID-19…
0
Accelerate your COVID-19 bioanalytical research while saving time and reducing cost
Wednesday 18 November 2020 11:00 [EST] 08:00 [PST] 16:00 [GMT] Alternative time zones REGISTER NOW The pharmaceutical industry is in…
0
COVID-19 biomarkers identified that could diagnose and predict outcomes
Three blood metabolites have been identified by Canadian researchers that appear to be affected by COVID-19, which could be measured in…
0
What is the extent of SARS-CoV-2 immunity post-exposure?
The question of COVID-19 immunity is on everyone’s lips. It is crucial to understand how immunity develops post-exposure to the virus…